Literature DB >> 32698671

Safety considerations for nanoparticle gene delivery in pediatric brain tumors.

Kathryn M Luly1, John Choi2, Yuan Rui1,3, Jordan J Green1,2,3,4,5,6, Eric M Jackson2.   

Abstract

Current standard of care for many CNS tumors involves surgical resection followed by chemotherapy and/or radiation. Some pediatric brain tumor types are infiltrative and diffuse in nature, which reduces the role for surgery. Furthermore, children are extremely vulnerable to neurological sequelae from surgery and radiation therapy, thus alternative approaches are in critical need. As molecular targets underlying various cancers become more clearly defined, there is an increasing push for targeted gene therapies. Viral vectors and nonviral nanoparticles have been thoroughly investigated for gene delivery and show promise as vectors for gene therapy for pediatric brain cancer. Here, we review inorganic and organic materials in development for nanoparticle gene delivery to the brain with a particular focus on safety.

Entities:  

Keywords:  brain tumor; gene delivery; nanoparticles; pediatrics; safety

Mesh:

Year:  2020        PMID: 32698671      PMCID: PMC7441302          DOI: 10.2217/nnm-2020-0110

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   6.096


  77 in total

Review 1.  Diffusion in brain extracellular space.

Authors:  Eva Syková; Charles Nicholson
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

Review 2.  Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology.

Authors:  M H A Jansen; D G van Vuurden; W P Vandertop; G J L Kaspers
Journal:  Cancer Treat Rev       Date:  2011-07-20       Impact factor: 12.111

Review 3.  Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.

Authors:  Vivienne H Tam; Chris Sosa; Rui Liu; Nan Yao; Rodney D Priestley
Journal:  Int J Pharm       Date:  2016-10-18       Impact factor: 5.875

Review 4.  Gold nanoparticles for nucleic acid delivery.

Authors:  Ya Ding; Ziwen Jiang; Krishnendu Saha; Chang Soo Kim; Sung Tae Kim; Ryan F Landis; Vincent M Rotello
Journal:  Mol Ther       Date:  2014-03-06       Impact factor: 11.454

5.  Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition.

Authors:  Abhishek Bavle; Jeremy Jones; Frank Y Lin; Amy Malphrus; Adekunle Adesina; Jack Su
Journal:  Pediatr Hematol Oncol       Date:  2017-10-17       Impact factor: 1.969

6.  Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model.

Authors:  João Conde; Nuria Oliva; Yi Zhang; Natalie Artzi
Journal:  Nat Mater       Date:  2016-07-25       Impact factor: 43.841

7.  Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.

Authors:  Susan N Chi; Mary Ann Zimmerman; Xiaopan Yao; Kenneth J Cohen; Peter Burger; Jaclyn A Biegel; Lucy B Rorke-Adams; Michael J Fisher; Anna Janss; Claire Mazewski; Stewart Goldman; Peter E Manley; Daniel C Bowers; Anne Bendel; Joshua Rubin; Christopher D Turner; Karen J Marcus; Liliana Goumnerova; Nicole J Ullrich; Mark W Kieran
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

8.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

9.  Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.

Authors:  Chenchen Bi; Aiping Wang; Yongchao Chu; Sha Liu; Hongjie Mu; Wanhui Liu; Zimei Wu; Kaoxiang Sun; Youxin Li
Journal:  Int J Nanomedicine       Date:  2016-12-07

10.  Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.

Authors:  Adam W Studebaker; Brian J Hutzen; Christopher R Pierson; Kellie B Haworth; Timothy P Cripe; Eric M Jackson; Jeffrey R Leonard
Journal:  Mol Ther Oncolytics       Date:  2017-05-25       Impact factor: 7.200

View more
  2 in total

1.  Photocrosslinked Bioreducible Polymeric Nanoparticles for Enhanced Systemic siRNA Delivery as Cancer Therapy.

Authors:  Johan Karlsson; Stephany Y Tzeng; Shayan Hemmati; Kathryn M Luly; Olivia Choi; Yuan Rui; David R Wilson; Kristen L Kozielski; Alfredo Quiñones-Hinojosa; Jordan J Green
Journal:  Adv Funct Mater       Date:  2021-02-22       Impact factor: 19.924

Review 2.  Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers.

Authors:  Clara Guido; Clara Baldari; Gabriele Maiorano; Angela Mastronuzzi; Andrea Carai; Concetta Quintarelli; Biagio De Angelis; Barbara Cortese; Giuseppe Gigli; Ilaria Elena Palamà
Journal:  Diagnostics (Basel)       Date:  2022-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.